Abstract
The application of capillary electrophoresis (CE) combined with highly sensitive inductively-coupled-plasma mass spectrometric (ICP-MS) detection allows the interactions of metal complexes with biomolecules to be characterized. This technique has been used to provide new insights into the mode of action of the ruthenium-based anticancer drug candidate indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019). While the compound binds rapidly and efficiently to serum proteins, especially albumin, its reactivity towards the model DNA compound 2'-deoxyguanosine 5'-monophosphate (5'-dGMP) is moderate.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / blood
-
Antineoplastic Agents / chemistry*
-
Antineoplastic Agents / pharmacology
-
Binding Sites
-
Clinical Trials as Topic
-
DNA / chemistry
-
Deoxyguanine Nucleotides / chemistry
-
Electrophoresis, Capillary / methods*
-
Humans
-
Indazoles / blood
-
Indazoles / chemistry*
-
Indazoles / pharmacology
-
Mass Spectrometry / methods*
-
Molecular Conformation
-
Organometallic Compounds
-
Ruthenium Compounds / blood
-
Ruthenium Compounds / chemistry*
-
Ruthenium Compounds / pharmacology
-
Serum Albumin / chemistry*
-
Spectrophotometry, Ultraviolet
-
Structure-Activity Relationship
Substances
-
Antineoplastic Agents
-
Deoxyguanine Nucleotides
-
Indazoles
-
Organometallic Compounds
-
Ruthenium Compounds
-
Serum Albumin
-
indazolium trans-(tetrachlorobis(1H-indazole)ruthenate (III))
-
2'-deoxyguanosine 5'-phosphate
-
DNA